asymptomatic group were recognized because of abnormalities in the liver studies, particularly the alkaline phosphatase, evidence of a lipid disorder or hepatomegaly. All patients in this group had a serum bilirubin of less than 1.2 mg/ dl. Patients in the active group had symptoms referable to chronic liver disease. These patients were generally referred for evaluation because of active liver disease, jaundice, or pruritis. In this group of 32 patients, there were 12 who had been treated for periods longer than 3 months with corticosteroids in varying dosages. The patients in the advanced group were jaundiced with severe cholestasis and evidence of progressive liver failure. Five of the seven patients in this category died during the period of observation.
Liver biopsy specimens were handled to prevent trace metal contamination. The tissue was freeze-dried and the dry weight determined. The dried tissue was wet-ashed with nitric-sulfuric acid, diluted and analyzed for copper by atomic absorption spectrophotometry utilizing peak-retrieval circuitry [14] . Hepatic copper values are expressed as ,sg/ g liver (dry weight). Based on the literature and analysis in patients with a variety of diseases, 50 jsg/ g or less was considered to be normal [5, 8] . Figure 1 shows the individual hepatic copper values for each of the 56 patients in relationship to the clinical stage. In the asymptomatic group, hepatic copper was 114 ± 81 jg/g (mean ± S.D.) with a range of 32-298 jg/g. Thirteen of the 17 values were abnormal, although only one exceeded 250 pg/g, the level which might be confused with Wilson's disease [6, 7] . In the active stage, the hepatic copper level was 324 ± 292,ug/g (mean ± S.D.) with a range of 249 ;,g/g. Twenty [6, 15] , whereas the excess copper is in the supernatant fraction in PBC [16] . In addition, the copper-binding protein demonstrated in the periportal hepatocytes of patients with prolonged cholestasis [17] , particularly the form observed in PBC [18] appears to [6, 7, 8] . The extremely elevated levels noted during the advanced stage of PBC, mean value of 1,090 ug/ g, were associated with hepatic failure. Six of the seven patients in this group died as a result of the disease. This relationship between the hepatic copper levels and the stages of the disease supports the involvement of copper toxicity in the progression of PBC rather than the initiation of the disease, as appears to be the case in Wilson's disease.
RESULTS
Between the asymptomatic and the advanced stages were patients judged to be in an active phase of the disease. In this group, the values ranged from normal to 1, 249 Ag/g with a mean of 342 ,g/g. Initially, all patients studied in this phase of the disease had elevated hepatic copper levels but, as the series was extended, several were observed to be normal or near normal. Therefore, it appears that PBC can be symptomatic without significant elevation of hepatic copper. Analysis of these patients disclosed that 4 of 5 with normal levels had been treated previously with corticosteroids. Corticosteroid therapy-has been widely used for chronic active hepatitis and, because of confusion with regard to the diagnosis, is occasionally prescribed for the patient with PBC. Corticosteroid therapy has been considered to be contraindicated in PBC because of potentiation of bone disease [12] and, in one published series, the absence of a response was used to differentiate PBC from chronic active hepatitis [19] . Nevertheless, some patients with established PBC do appear to show clinical improvement with this therapy, although the benefit may not be great enough to justify long-term treatment. In the current study those patients who were normal or near normal during the active stage of the disease were very likely to have been treated with corticosteroids. Six of nine patients who received steroid therapy during this study showed a mild decrease in hepatic copper. These observations suggest that corticosteroid therapy facilitates the biliary excretion of copper perhaps by decreasing the inflammatory process, though the mechanism has not been demonstrated. This response may occur in the absence of significant clinical improvement and suggests that corticosteroids have an effect in PBC that has not been recognized previously.
Controlled studies are in progress to evaluate therapy with d-penicillamine in PBC because of the abnormal hepatic copper levels [9, 11] . Because of the chronicity of PBC it may not be possible to determine the beneficial effect of this therapy for several years. Any beneficial effect may be difficult to document unless the patients are observed for prolonged periods since it is possible that treatment prevents or delays the onset of hepatic failure, rather than reversing the process present at the time of initiation of therapy. If copper removal were the only beneficial effect of dpenicillamine in PBC, one would not expect much change in patients in the asymptomatic phase of the disease. It should be remembered that d-penicillamine also has the potential for altering immune responses [20] and retarding fibrogenesis [21, 22] , factors which appear to be operative in the pathogenesis of PBC. Since therapy with d-penicillamine is frequently associated with side-effects, it seems prudent to await results of the controlled studies before initiating treatment in individual patients. Until such information is available, it may be appropriate to restrict copper intake as is done for therapy of Wilson's disease.
